# Jeffrey I. Weitz

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/jeffrey-i-weitz/

## Facts

| Field | Value |
| --- | --- |
| Citations | 75,436 |
| Field | Venous Thromboembolism Diagnosis and Management |
| h-index | 119 |
| i10-index | 488 |
| Last Known Institution | McMaster University Medical Centre |
| OpenAlex ID | https://openalex.org/A5082464840 |
| ORCID iD | https://orcid.org/0000-0002-1092-7550 |
| Works | 767 |

## Researcher papers

- [Edoxaban versus Warfarin in Patients with Atrial Fibrillation](https://scholariq.org/papers/edoxaban-versus-warfarin-in-patients-with-atrial-fibrillation/)
- [Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials](https://scholariq.org/papers/comparison-of-the-efficacy-and-safety-of-new-oral-anticoagulants-with-warfarin/)
- [COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up](https://scholariq.org/papers/covid-19-and-thrombotic-or-thromboembolic-disease-implications-for-prevention/)
- [The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation](https://scholariq.org/papers/the-2018-european-heart-rhythm-association-practical-guide-on-the-use-of-non/)
- [Idarucizumab for Dabigatran Reversal](https://scholariq.org/papers/idarucizumab-for-dabigatran-reversal/)
- [A Comparison of Low-Molecular-Weight Heparin Administered Primarily at Home with Unfractionated Heparin Administered in the Hospital for Proximal Deep-Vein Thrombosis](https://scholariq.org/papers/a-comparison-of-low-molecular-weight-heparin-administered-primarily-at-home-with/)
- [Idarucizumab for Dabigatran Reversal — Full Cohort Analysis](https://scholariq.org/papers/idarucizumab-for-dabigatran-reversal-full-cohort-analysis/)
- [Parenteral anticoagulants in heart disease: Current status and perspectives (Section II)](https://scholariq.org/papers/parenteral-anticoagulants-in-heart-disease-current-status-and-perspectives/)
- [Vitamin K antagonists in heart disease: Current status and perspectives (Section III)](https://scholariq.org/papers/vitamin-k-antagonists-in-heart-disease-current-status-and-perspectives-section/)
- [New Oral Anticoagulants in Atrial Fibrillation and Acute Coronary Syndromes](https://scholariq.org/papers/new-oral-anticoagulants-in-atrial-fibrillation-and-acute-coronary-syndromes/)
- [The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary](https://scholariq.org/papers/the-2018-european-heart-rhythm-association-practical-guide-on-the-use-of-non-2/)

## Researcher topics

- [Venous Thromboembolism Diagnosis and Management](https://scholariq.org/topics/venous-thromboembolism-diagnosis-and-management-2/)
- [Atrial Fibrillation Management and Outcomes](https://scholariq.org/topics/atrial-fibrillation-management-and-outcomes/)
- [Blood Coagulation and Thrombosis Mechanisms](https://scholariq.org/topics/blood-coagulation-and-thrombosis-mechanisms/)
- [Antiplatelet Therapy and Cardiovascular Diseases](https://scholariq.org/topics/antiplatelet-therapy-and-cardiovascular-diseases/)
- [Heparin-Induced Thrombocytopenia and Thrombosis](https://scholariq.org/topics/heparin-induced-thrombocytopenia-and-thrombosis/)

## Researcher university

- [McMaster University Medical Centre](https://scholariq.org/institutions/mcmaster-university-medical-centre/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.